Additionally, compounds targeting the NTD or the DBD domains of AR have received attention, as they may affect constitutively active AR splice variants (ARVs), which lack the entire LBD and are involved in castrate resistant prostate cancer (CRPC) [46,47,48,49,50,51,52,53,54]. Here, AR is linked to prostate carcinoma.